Dimension Therapeutics Inc (DMTX) Given Consensus Rating of “Hold” by Analysts
Shares of Dimension Therapeutics Inc (NASDAQ:DMTX) have been given an average recommendation of “Hold” by the eight research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.08.
Several research analysts have recently issued reports on the stock. Chardan Capital reiterated a “buy” rating on shares of Dimension Therapeutics in a research note on Friday. Wells Fargo & Co cut shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $9.00 to $6.00 in a report on Tuesday, October 3rd. Citigroup raised shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $5.50 to $6.00 in a report on Tuesday, October 3rd. ValuEngine raised shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 30th. Finally, Canaccord Genuity cut shares of Dimension Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the company from $12.00 to $3.41 in a report on Wednesday, August 30th.
A number of hedge funds have recently made changes to their positions in DMTX. Goldman Sachs Group Inc. increased its holdings in Dimension Therapeutics by 206.7% during the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 54,231 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Dimension Therapeutics during the third quarter valued at approximately $600,000. Kassirer Asset Management Corp purchased a new stake in Dimension Therapeutics during the third quarter valued at approximately $952,000. Finally, K2 Principal Fund L.P. purchased a new stake in Dimension Therapeutics during the third quarter valued at approximately $960,000. 70.33% of the stock is owned by institutional investors and hedge funds.
Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.20). The firm had revenue of $4.48 million during the quarter. Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. analysts expect that Dimension Therapeutics will post -1.99 EPS for the current fiscal year.
WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/25/dimension-therapeutics-inc-dmtx-given-consensus-rating-of-hold-by-analysts-2.html.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.